Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2010-09-20

FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)

View source ↗

Summary

FDA approved a supplemental application for fluoxetine hydrochloride by PAI Holdings to modify the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fluoxetine (Fluoxetine)

Snippet

SUPPL AP for FLUOXETINE (FLUOXETINE HYDROCHLORIDE)